Literature DB >> 7489977

The clinical significance of p53 gene mutation in hepatocellular carcinomas from Japan.

H Hayashi1, K Sugio, T Matsumata, E Adachi, K Takenaka, K Sugimachi.   

Abstract

To clarify the clinical significance of the mutation of p53 gene in hepatocellular carcinoma (HCC), 90 resected specimens from Japanese patients were assayed using a polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. p53 mutations were detected in 25 cases (27.8%) at exons 4, 5, 6, 7, and 8, and the most frequent region of the mutation was at exons 5 and 7. No statistically significant correlation was observed between the p53 mutations and the clinical features except for the preoperative alpha-fetoprotein (AFP) level (P < .05). According to the pathological features, prognostic factors, such as size of the tumor, vascular invasion, fibrous capsule infiltration, and intrahepatic metastasis, showed no relationship to the existence of the mutation. However, p53 mutations were significantly associated with the degree of differentiation of HCC; that is, the mutation was found in 19 cases of 53 poorly differentiated HCCs (35.9%) and 2 of 3 cases of anaplastic HCCs (66.7%). The presence of p53 mutations was associated with a shortened cancer-free survival (P < .001, by log rank test) and a shortened survival (P < .05). A multivariate analysis by the Cox regression analysis showed that the p53 mutations were an unfavorable prognostic factor related to recurrence (P < .005), which is especially significant within the first postoperative year. These results suggest that the mutations of p53 gene of HCC might be an independent prognostic predictor to help in the selection of candidates who should undergo more intensive postoperative treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7489977

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  25 in total

1.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma.

Authors:  Hyun Goo Woo; Xin Wei Wang; Anuradha Budhu; Yun Hee Kim; So Mee Kwon; Zhao-You Tang; Zongtang Sun; Curtis C Harris; Snorri S Thorgeirsson
Journal:  Gastroenterology       Date:  2010-11-19       Impact factor: 22.682

2.  Codon 249 mutations of p53 gene in development of hepatocellular carcinoma.

Authors:  Xiao-Mou Peng; Wen-Wei Peng; Ji-Lu Yao
Journal:  World J Gastroenterol       Date:  1998-04       Impact factor: 5.742

3.  A locked nucleic acid clamp-mediated PCR assay for detection of a p53 codon 249 hotspot mutation in urine.

Authors:  Selena Y Lin; Veerpal Dhillon; Surbhi Jain; Ting-Tsung Chang; Chi-Tan Hu; Yih-Jyh Lin; Shun-Hua Chen; Kung-Chao Chang; Wei Song; Lixin Yu; Timothy M Block; Ying-Hsiu Su
Journal:  J Mol Diagn       Date:  2011-07-02       Impact factor: 5.568

Review 4.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

5.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

6.  P53 immunohistochemical scoring: an independent prognostic marker for patients after hepatocellular carcinoma resection.

Authors:  Lun-Xiu Qin; Zhao-You Tang; Zeng-Chen Ma; Zhi-Quan Wu; Xin-Da Zhou; Qing-Hai Ye; Yuan Ji; Li-Wen Huang; Hu-Liang Jia; Hui-Chuan Sun; Lu Wang
Journal:  World J Gastroenterol       Date:  2002-06       Impact factor: 5.742

7.  The significance of p53 mutations as an indicator of the biological behavior of recurrent hepatocellular carcinomas.

Authors:  H Sugo; S Takamori; K Kojima; T Beppu; S Futagawa
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 8.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

9.  TP53 mutation is associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji; Li-Ke Yu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

10.  Detection of mutant p53 in hepatocellular cancer from Turkey and its correlation with clinicopathologic parameters.

Authors:  Cem Cengiz; Ulus S Akarca; Erdem Goker; Gul Yuce
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.